Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid for prevention of radiographic progression in early rheumatoid arthritis with low disease activity
2013-005001-31Phase 3Terminated
- Sponsor
- Dra. Carmen Gómez Vaquero (Servicio de ReumatologÃa del Hospital Universiari de Bellvitge - Idibell)
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid in rheumatoid arthritis (RA) (2 arms), sponsored by Dra. Carmen Gómez Vaquero (Servicio de ReumatologÃa del Hospital Universiari de Bellvitge - Idibell). Primary endpoint: Progression of radiological damage after two years. Started Feb 2014; status: terminated.
02
Drugs
zoledronic acid
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2013-005001-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005001-31.